An open-label study of the effect of Herceptin [trastuzumab] monotherapy on tumor response in women with metastatic breast cancer with HER2 [human epidermal growth factor receptor-2] overexpression/amplification

Trial Profile

An open-label study of the effect of Herceptin [trastuzumab] monotherapy on tumor response in women with metastatic breast cancer with HER2 [human epidermal growth factor receptor-2] overexpression/amplification

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2010

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 Jan 2008 Status changed from in progress to completed.
    • 16 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top